Soodeh Salimi Khaligh

Dr. Soodeh Salimi Khaligh

Sabancı University, Istanbul, İstanbul, Turkey (Türkiye)
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2024 in Journal of Environmental Management
Verified
Journal Article
Closed access
Vahid VatanpourVahid Vatanpour
Vahid Vatanpour
Soodeh Salimi KhalighSoodeh Salimi Khaligh
Soodeh Salimi Khaligh
SSSimge Sertgumec
Simge Sertgumec
GCGamze Ceylan-Perver
Gamze Ceylan-Perver
AYAyse Yuksekdag
Ayse Yuksekdag
İKİsmail Koyuncu
İsmail Koyuncu

4 July 2016 in Journal of Chemical Technology & Biotechnology
Verified
Journal Article
Closed access
PDF file
Soodeh Salimi KhalighSoodeh Salimi Khaligh
Soodeh Salimi Khaligh
NYNevin Yagci
Nevin Yagci
CBCigdem Balcik
Cigdem Balcik
BOBahar Ozbey
Bahar Ozbey
BKBulent Keskinler
Bulent Keskinler
SSSeval Sozen
Seval Sozen

21 October 2016 in Journal of Chemical Technology & Biotechnology
Verified
Journal Article
Closed access
PDF file
Soodeh Salimi KhalighSoodeh Salimi Khaligh
Soodeh Salimi Khaligh
NYNevin Yagci
Nevin Yagci
EUEmine Ubay‐Cokgor
Emine Ubay‐Cokgor
CKCansu Karaca
Cansu Karaca
BABusra Alli
Busra Alli
SSSeval Sözen
Seval Sözen

20 December 2024 in Biosensors
Verified
Journal Article
Open access
PDF file
Soodeh Salimi KhalighSoodeh Salimi Khaligh
Soodeh Salimi Khaligh
Fahd Khalid-SalakoFahd Khalid-Salako
Fahd Khalid-Salako
HKHasan Kurt
Hasan Kurt
MYMeral Yüce
Meral Yüce
Vascular endothelial growth factor (VEGF) is a critical angiogenesis biomarker associated with various pathological conditions, including cancer. This study leverages pre-biotinylated FcγRI interactions with IgG1-type monoclonal antibodies to develop a sensitive VEGF detection method. Utilizing surface plasmon resonance (SPR) technology, we characterized the binding dynamics of immobilized biotinylated FcγRI to an IgG1-type antibody, Bevacizumab (AVT), through kinetic studies and investigated suitable conditions for sensor surface regeneration. Subsequently, we characterized the binding of FcγRI-captured AVT to VEGF, calculating kinetic constants and binding affinity. A calibration curve was established to analyze the VEGF quantification capacity and accuracy of the biosensor, computing the limits of blank, detection, and quantification at a 95% confidence interval. Additionally, the specificity of the biosensor for VEGF over other protein analytes was assessed. This innovative biomimetic approach enabled FcγRI-mediated site-specific AVT capture, establishing a stable and reusable platform for detecting and accurately quantifying VEGF. The results indicate the effectiveness of the plasmonic sensor platform for VEGF detection, making it suitable for research applications and, potentially, clinical diagnostics. Utilizing FcγRI-IgG1 antibody binding, this study highlights the industrial and clinical value of advanced biosensing technologies, offering insights to enhance therapeutic monitoring and improve outcomes in anti-VEGF therapies.

14 December 2022 in Waste and Biomass Valorization
Verified
Journal Article
Closed access
PDF file
Soodeh Salimi KhalighSoodeh Salimi Khaligh
Soodeh Salimi Khaligh
EPEce Polat
Ece Polat
MAMahmut Altinbas
Mahmut Altinbas